(i) To compare infections caused by carbapenem-susceptible (CS) and carbapenemase producing carbapenem-resistant Enterobacteriaceae (CP-CRE); (ii) to evaluate the clinical effectiveness of the double-carbapenem (DC) regimen in comparison with the best available treatment (BAT) in infections caused by CP-CRE; and (iii) to determine the exact minimal inhibitory concentrations (MICs) of meropenem/ertapenem (MEM/ETP) and the degree of in vitro ETP+MEM synergism in subjects receiving the DC.
Role of double-carbapenem regimen in the treatment of infections due to carbapenemase producing carbapenem-resistant enterobacteriaceae: a single-center, observational study / Cancelli, F; Oliva, A; De Angelis, M; Mascellino, M T; Mastroianni, C M; Vullo, V. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - (2018), pp. 1-8. [10.1155/2018/2785696]
Role of double-carbapenem regimen in the treatment of infections due to carbapenemase producing carbapenem-resistant enterobacteriaceae: a single-center, observational study
Cancelli, F;Oliva, A;De Angelis, M;Mastroianni, C M;Vullo, V
2018
Abstract
(i) To compare infections caused by carbapenem-susceptible (CS) and carbapenemase producing carbapenem-resistant Enterobacteriaceae (CP-CRE); (ii) to evaluate the clinical effectiveness of the double-carbapenem (DC) regimen in comparison with the best available treatment (BAT) in infections caused by CP-CRE; and (iii) to determine the exact minimal inhibitory concentrations (MICs) of meropenem/ertapenem (MEM/ETP) and the degree of in vitro ETP+MEM synergism in subjects receiving the DC.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cancelli_Role_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.24 MB
Formato
Adobe PDF
|
1.24 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
